Adam C. Palmer, PhD, on Immune Checkpoint Inhibitors: Additive to or Synergistic With Other Treatments?
AACR Virtual Annual Meeting 2020 IIAdam C. Palmer, PhD, of the University of North Carolina at Chapel Hill, discusses combining immune checkpoint inhibitors with other cancer therapies to provide patients with more chances of a response. In principle, similar benefits may result from sequential or biomarker-stratified treatments, which could be valuable in cases where toxicities may prevent full-dose combinations (Abstract 1047).
Related Videos
Antoni Ribas, MD, PhD, on Turning Science Into Life-Saving Care
Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, summarizes the opening plenary session that addressed epigenetics and early detection...
Ralph R. Weichselbaum, MD, on Radiotherapy and Immunotherapy in Oligometastatic Disease
Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunot...
Alfonso Bencomo Álvarez, PhD, on ALL, AML, and CML: Survival for Hispanic Patients Living Near the US/Mexico Border
Alfonso Bencomo Álvarez, PhD, of Texas Tech University Health Sciences Center, discusses his retrospective study of the incidence and survival for patients with hematologic m...
Silvia Formenti, MD, on Testing Radiation and Immune Checkpoint Blockade in Different Tumor Settings
Silvia Formenti, MD, of Weill Cornell Medical College, discusses her continuing work, and the promising results emerging, in combining radiotherapy with immunotherapy to boos...
Nasser K. Altorki, MD, on Lung Cancer: Radiotherapy and Immune Checkpoint Blockade in the Neoadjuvant Setting
Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint b...
